Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 17/20 | 0.78 |
| ▸ | AURKA | O14965 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3973368 | 0.88 | ERBB2 (1.00) | EGFRERBB2AURKA | |
| SCHEMBL4255492 | 0.88 | EGFR (0.80) | EGFRERBB2AURKA | |
| SCHEMBL1105428 | 0.87 | EGFR (1.00) | EGFRERBB2AURKA | |
| Diethylamine SCHEMBL4255489 | 0.86 | EGFR (0.89) | EGFRERBB2AURKA | |
| SCHEMBL1096310 | 0.86 | ERBB2 (1.00) | EGFRERBB2AURKA | |
| SCHEMBL3974260 | 0.84 | EGFR (1.00) | EGFRERBB2AURKA | |
| SCHEMBL13873522 | 0.82 | EGFR (0.78) | EGFRERBB2AURKA | |
| SCHEMBL13884430 | 0.82 | ERBB2 (0.81) | EGFRERBB2AURKA | |
| SCHEMBL13873526 | 0.81 | EGFR (0.86) | EGFRERBB2AURKA | |
| SCHEMBL12851528 | 0.80 | EGFR (0.74) | EGFRERBB2AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | claimed |
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | claimed |
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
| WO-2009055299-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111810-A1 | SUBSTITUTED PYRIMIDINE-5-CARBOXAMIDE AND 5-CARBOXYLIC ESTER KINASE INHIBITORS | MAP3K5, FLT3, MAP3K19 | EGFR 309/4885ERBB2 67/4885AURKA 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.